Tim Opler covers the evolving cardiovascular drug field, which is accelerating due to the high unmet need.
Biopharma Market Update
Stifel
Tim Opler
Research
73 Pages
Key Takeaways
Cardio Mortality Still Huge: Cardiovascular disease remains the world’s leading killer with ~20 million deaths per year globally, meaning even modestly effective new drugs could impact an enormous patient population.
New Drug Mechanisms Emerging: Beyond statins and PCSK9 inhibitors, new approaches targeting pathways like Lp(a), inflammation, and RNA-based therapies are advancing, potentially addressing residual cardiovascular risk that persists even after LDL reduction.
Massive Patient Opportunity: Certain emerging targets such as Lp(a) affect roughly 20% of the global population (~1.5 billion people), creating one of the largest untapped markets in medicine if effective therapies prove successful.